New drug combo may keep severe colitis patients out of the hospital
NCT ID NCT07258771
First seen Jan 10, 2026 · Last updated Jun 22, 2026 · Updated 26 times
Summary
This study tests whether adding upadacitinib (Rinvoq) to standard steroid treatment helps people with a severe ulcerative colitis flare-up recover faster and avoid emergency care or surgery. About 110 adults with acute severe ulcerative colitis will be randomly assigned to get either steroids alone or steroids plus upadacitinib. The main goal is to see if more people in the combo group have a quick improvement within 5 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS ACUTE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
upadacitinib (Rinvoq) and methylprednisolone (Solumedrol)
What this could lead to
If it works, this could offer a faster, more effective way to control severe flare-ups and reduce the need for emergency hospital stays or surgery.
What could go wrong
This is a single-center, early-phase trial with only 110 participants, so results may not apply broadly. Upadacitinib also carries risks like infection and blood clots.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.